These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 32983101)

  • 21. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis.
    Ribaldone DG; Pellicano R; Vernero M; Caviglia GP; Saracco GM; Morino M; Astegiano M
    Scand J Gastroenterol; 2019 Apr; 54(4):407-413. PubMed ID: 30945576
    [No Abstract]   [Full Text] [Related]  

  • 22. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
    Barré A; Colombel JF; Ungaro R
    Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy.
    Baird AC; Mallon D; Radford-Smith G; Boyer J; Piche T; Prescott SL; Lawrance IC; Tulic MK
    World J Gastroenterol; 2016 Nov; 22(41):9104-9116. PubMed ID: 27895398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered distribution and function of splenic innate lymphoid cells in adult chronic immune thrombocytopenia.
    Audia S; Moulinet T; Ciudad-Bonté M; Samson M; Facy O; Ortega-Deballon P; Saas P; Bonnotte B
    J Autoimmun; 2018 Sep; 93():139-144. PubMed ID: 30055825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T-Bet Controls Cellularity of Intestinal Group 3 Innate Lymphoid Cells.
    Schroeder JH; Meissl K; Hromadová D; Lo JW; Neves JF; Howard JK; Helmby H; Powell N; Strobl B; Lord GM
    Front Immunol; 2020; 11():623324. PubMed ID: 33603753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
    Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
    Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Innate Lymphoid Cells and Inflammatory Bowel Disease.
    Peng V; Jaeger N; Colonna M
    Adv Exp Med Biol; 2022; 1365():97-112. PubMed ID: 35567743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enrichment of IL-17A
    Li J; Doty AL; Tang Y; Berrie D; Iqbal A; Tan SA; Clare-Salzler MJ; Wallet SM; Glover SC
    Clin Exp Immunol; 2017 Oct; 190(1):143-153. PubMed ID: 28586085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aryl hydrocarbon receptor signaling involves in the human intestinal ILC3/ILC1 conversion in the inflamed terminal ileum of Crohn's disease patients.
    Li J; Doty A; Glover SC
    Inflamm Cell Signal; 2016; 3(3):. PubMed ID: 28286805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Compartment-specific distribution of human intestinal innate lymphoid cells is altered in HIV patients under effective therapy.
    Krämer B; Goeser F; Lutz P; Glässner A; Boesecke C; Schwarze-Zander C; Kaczmarek D; Nischalke HD; Branchi V; Manekeller S; Hüneburg R; van Bremen T; Weismüller T; Strassburg CP; Rockstroh JK; Spengler U; Nattermann J
    PLoS Pathog; 2017 May; 13(5):e1006373. PubMed ID: 28505204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy in inflammatory bowel disease.
    Ahluwalia JP
    Med Clin North Am; 2012 May; 96(3):525-44, x. PubMed ID: 22703854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Innate Lymphoid Cells in Inflammatory Bowel Disease.
    Li J; Glover SC
    Arch Immunol Ther Exp (Warsz); 2018 Dec; 66(6):415-421. PubMed ID: 30155762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
    United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type 2 Diabetes Mellitus and Latent Tuberculosis Infection Moderately Influence Innate Lymphoid Cell Immune Responses in Uganda.
    Ssekamatte P; Nakibuule M; Nabatanzi R; Egesa M; Musubika C; Bbuye M; Hepworth MR; Doherty DG; Cose S; Biraro IA
    Front Immunol; 2021; 12():716819. PubMed ID: 34512639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome.
    Raddatz D; Bockemühl M; Ramadori G
    Eur J Gastroenterol Hepatol; 2005 May; 17(5):547-57. PubMed ID: 15827446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.
    Biancheri P; Brezski RJ; Di Sabatino A; Greenplate AR; Soring KL; Corazza GR; Kok KB; Rovedatti L; Vossenkämper A; Ahmad N; Snoek SA; Vermeire S; Rutgeerts P; Jordan RE; MacDonald TT
    Gastroenterology; 2015 Nov; 149(6):1564-1574.e3. PubMed ID: 26170138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Commensal and Pathogenic Bacteria Indirectly Induce IL-22 but Not IFNγ Production From Human Colonic ILC3s via Multiple Mechanisms.
    Castleman MJ; Dillon SM; Purba CM; Cogswell AC; Kibbie JJ; McCarter MD; Santiago ML; Barker E; Wilson CC
    Front Immunol; 2019; 10():649. PubMed ID: 30984202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study.
    Bor R; Fábián A; Matuz M; Szepes Z; Farkas K; Miheller P; Szamosi T; Vincze Á; Rutka M; Szántó K; Bálint A; Nagy F; Milassin Á; Tóth T; Zsigmond F; Bajor J; Müllner K; Lakner L; Papp M; Salamon Á; Horváth G; Sarang K; Schäfer E; Sarlós P; Palatka K; Molnár T
    Expert Opin Biol Ther; 2020 Feb; 20(2):205-213. PubMed ID: 31782939
    [No Abstract]   [Full Text] [Related]  

  • 40. Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease.
    Restellini S; Khanna R; Afif W
    Inflamm Bowel Dis; 2018 Sep; 24(10):2165-2172. PubMed ID: 29788272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.